Sunrise Realty Trust, Inc. (SUNS)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023
Interest and Dividend Income	13.78	10.84	0.73
Total Interest Expense	0.55	0.22	-
Net Interest Income	13.22	10.63	0.73
Revenue Before Loan Losses	13.22	10.63	0.73
Provision for Loan Losses	0.16	0.04	-
Revenue	13.07	10.59	0.73
Revenue Growth (YoY)	-	1342.10%	-
Cost of Services Provided	3.88	2.78	0.03
Total Operating Expenses	4.46	3.12	0.03
Operating Income	8.61	7.47	0.7
EBT Excluding Unusual Items	8.61	7.47	0.7
Other Unusual Items	-0.4	-0.6	-
Pretax Income	8.21	6.87	0.7
Net Income	8.21	6.87	0.7
Net Income to Common	8.21	6.87	0.7
Net Income Growth	-	875.81%	-
Shares Outstanding (Basic)	8	7	7
Shares Outstanding (Diluted)	8	7	7
Shares Change (YoY)	-	-0.77%	-
EPS (Basic)	1.04	1.01	0.10
EPS (Diluted)	1.02	1.00	0.09
EPS Growth	-	1011.11%	-
Dividend Per Share	0.930	0.630	-
Operating Margin	65.86%	70.53%	95.86%
Profit Margin	62.80%	64.87%	95.86%
Revenue as Reported	10.63	10.63	0.73

Updated May 7, 2025. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.

SEC Filings: 10-K · 10-Q